Nuclear factor κ B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy
NF-kappaB is an important transcription factor complex that appears to play a fundamental role in regulating acute inflammation through activation of the cytokine cascade and production of other pro-inflammatory mediators. There is increasing evidence that NF-kappaB is important in the pathobiology...
Gespeichert in:
Veröffentlicht in: | Intensive care medicine 1998-11, Vol.24 (11), p.1131-1138 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1138 |
---|---|
container_issue | 11 |
container_start_page | 1131 |
container_title | Intensive care medicine |
container_volume | 24 |
creator | CHRISTMAN, J. W LANCASTER, L. H BLACKWELL, T. S |
description | NF-kappaB is an important transcription factor complex that appears to play a fundamental role in regulating acute inflammation through activation of the cytokine cascade and production of other pro-inflammatory mediators. There is increasing evidence that NF-kappaB is important in the pathobiology of disease states such as SIRS, MODS and ARDS; therefore, therapeutic interventions aimed at limiting NF-kappaB activation and down-regulating production of inflammatory mediators could prove to be beneficial in decreasing host-derived tissue injury and organ dysfunction. Specific interventions that hold promise for suppressing NF-kappaB activation include the use of antioxidants, inhibition of NIK and the IKK signalsome, treatment with proteasome inhibitors, induction of endotoxin tolerance and, possibly the use of corticosteroids in selected patients. |
doi_str_mv | 10.1007/s001340050735 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69115815</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69115815</sourcerecordid><originalsourceid>FETCH-LOGICAL-p235t-ff8ec16569cea33cb34bab4bb7abf7c5887f9ef9c459f0220c750833f18500463</originalsourceid><addsrcrecordid>eNo9kLlOxDAURS0EgmGgpERygegCdrzFdDBik0bQQB29eGwIyobtgPJrfATfhBER1dPTOfcWF6EjSs4oIeo8EEIZJ0QQxcQWWlDO8ozmrNhGC8J4nnHJ8z20H8JbMpUUdBft6kJJrfgCtQ-jaSx47MDE3uPvL3x1gQEP9UcfocG-byyuOxxfLQ5TiLatTfpdA20LKTBhb8PQd-EXdxvftxZDt8Gd_cQR_IuN2KXaFPcwTAdox0ET7OF8l-j55vppdZetH2_vV5frbMiZiJlzhTVUCqmNBcZMxXgFFa8qBZVTRhSFcto6bbjQjuQ5MUqQgjFHC0EIl2yJTv96B9-_jzbEsq2DsU0Dne3HUEpNqSioSOLxLI5Vazfl4OsW_FTO-yR-MnMIBhrnoTN1-NeoTItqzX4AoFh1og</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69115815</pqid></control><display><type>article</type><title>Nuclear factor κ B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>CHRISTMAN, J. W ; LANCASTER, L. H ; BLACKWELL, T. S</creator><creatorcontrib>CHRISTMAN, J. W ; LANCASTER, L. H ; BLACKWELL, T. S</creatorcontrib><description>NF-kappaB is an important transcription factor complex that appears to play a fundamental role in regulating acute inflammation through activation of the cytokine cascade and production of other pro-inflammatory mediators. There is increasing evidence that NF-kappaB is important in the pathobiology of disease states such as SIRS, MODS and ARDS; therefore, therapeutic interventions aimed at limiting NF-kappaB activation and down-regulating production of inflammatory mediators could prove to be beneficial in decreasing host-derived tissue injury and organ dysfunction. Specific interventions that hold promise for suppressing NF-kappaB activation include the use of antioxidants, inhibition of NIK and the IKK signalsome, treatment with proteasome inhibitors, induction of endotoxin tolerance and, possibly the use of corticosteroids in selected patients.</description><identifier>ISSN: 0342-4642</identifier><identifier>EISSN: 1432-1238</identifier><identifier>DOI: 10.1007/s001340050735</identifier><identifier>PMID: 9876974</identifier><identifier>CODEN: ICMED9</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Anti-Inflammatory Agents - therapeutic use ; Antioxidants - therapeutic use ; Biological and medical sciences ; Cell Adhesion Molecules - immunology ; Cytokines - immunology ; Emergency and intensive care: infection, septic shock ; Glycoproteins - therapeutic use ; Humans ; I-kappa B Kinase ; Intensive care medicine ; Interleukins - immunology ; Medical sciences ; NF-kappa B - antagonists & inhibitors ; NF-kappa B - immunology ; Protein-Serine-Threonine Kinases - antagonists & inhibitors ; Steroids ; Systemic Inflammatory Response Syndrome - complications ; Systemic Inflammatory Response Syndrome - drug therapy ; Systemic Inflammatory Response Syndrome - immunology</subject><ispartof>Intensive care medicine, 1998-11, Vol.24 (11), p.1131-1138</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1601799$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9876974$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHRISTMAN, J. W</creatorcontrib><creatorcontrib>LANCASTER, L. H</creatorcontrib><creatorcontrib>BLACKWELL, T. S</creatorcontrib><title>Nuclear factor κ B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy</title><title>Intensive care medicine</title><addtitle>Intensive Care Med</addtitle><description>NF-kappaB is an important transcription factor complex that appears to play a fundamental role in regulating acute inflammation through activation of the cytokine cascade and production of other pro-inflammatory mediators. There is increasing evidence that NF-kappaB is important in the pathobiology of disease states such as SIRS, MODS and ARDS; therefore, therapeutic interventions aimed at limiting NF-kappaB activation and down-regulating production of inflammatory mediators could prove to be beneficial in decreasing host-derived tissue injury and organ dysfunction. Specific interventions that hold promise for suppressing NF-kappaB activation include the use of antioxidants, inhibition of NIK and the IKK signalsome, treatment with proteasome inhibitors, induction of endotoxin tolerance and, possibly the use of corticosteroids in selected patients.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antioxidants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cell Adhesion Molecules - immunology</subject><subject>Cytokines - immunology</subject><subject>Emergency and intensive care: infection, septic shock</subject><subject>Glycoproteins - therapeutic use</subject><subject>Humans</subject><subject>I-kappa B Kinase</subject><subject>Intensive care medicine</subject><subject>Interleukins - immunology</subject><subject>Medical sciences</subject><subject>NF-kappa B - antagonists & inhibitors</subject><subject>NF-kappa B - immunology</subject><subject>Protein-Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>Steroids</subject><subject>Systemic Inflammatory Response Syndrome - complications</subject><subject>Systemic Inflammatory Response Syndrome - drug therapy</subject><subject>Systemic Inflammatory Response Syndrome - immunology</subject><issn>0342-4642</issn><issn>1432-1238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kLlOxDAURS0EgmGgpERygegCdrzFdDBik0bQQB29eGwIyobtgPJrfATfhBER1dPTOfcWF6EjSs4oIeo8EEIZJ0QQxcQWWlDO8ozmrNhGC8J4nnHJ8z20H8JbMpUUdBft6kJJrfgCtQ-jaSx47MDE3uPvL3x1gQEP9UcfocG-byyuOxxfLQ5TiLatTfpdA20LKTBhb8PQd-EXdxvftxZDt8Gd_cQR_IuN2KXaFPcwTAdox0ET7OF8l-j55vppdZetH2_vV5frbMiZiJlzhTVUCqmNBcZMxXgFFa8qBZVTRhSFcto6bbjQjuQ5MUqQgjFHC0EIl2yJTv96B9-_jzbEsq2DsU0Dne3HUEpNqSioSOLxLI5Vazfl4OsW_FTO-yR-MnMIBhrnoTN1-NeoTItqzX4AoFh1og</recordid><startdate>19981101</startdate><enddate>19981101</enddate><creator>CHRISTMAN, J. W</creator><creator>LANCASTER, L. H</creator><creator>BLACKWELL, T. S</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19981101</creationdate><title>Nuclear factor κ B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy</title><author>CHRISTMAN, J. W ; LANCASTER, L. H ; BLACKWELL, T. S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p235t-ff8ec16569cea33cb34bab4bb7abf7c5887f9ef9c459f0220c750833f18500463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antioxidants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cell Adhesion Molecules - immunology</topic><topic>Cytokines - immunology</topic><topic>Emergency and intensive care: infection, septic shock</topic><topic>Glycoproteins - therapeutic use</topic><topic>Humans</topic><topic>I-kappa B Kinase</topic><topic>Intensive care medicine</topic><topic>Interleukins - immunology</topic><topic>Medical sciences</topic><topic>NF-kappa B - antagonists & inhibitors</topic><topic>NF-kappa B - immunology</topic><topic>Protein-Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>Steroids</topic><topic>Systemic Inflammatory Response Syndrome - complications</topic><topic>Systemic Inflammatory Response Syndrome - drug therapy</topic><topic>Systemic Inflammatory Response Syndrome - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHRISTMAN, J. W</creatorcontrib><creatorcontrib>LANCASTER, L. H</creatorcontrib><creatorcontrib>BLACKWELL, T. S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Intensive care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHRISTMAN, J. W</au><au>LANCASTER, L. H</au><au>BLACKWELL, T. S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nuclear factor κ B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy</atitle><jtitle>Intensive care medicine</jtitle><addtitle>Intensive Care Med</addtitle><date>1998-11-01</date><risdate>1998</risdate><volume>24</volume><issue>11</issue><spage>1131</spage><epage>1138</epage><pages>1131-1138</pages><issn>0342-4642</issn><eissn>1432-1238</eissn><coden>ICMED9</coden><abstract>NF-kappaB is an important transcription factor complex that appears to play a fundamental role in regulating acute inflammation through activation of the cytokine cascade and production of other pro-inflammatory mediators. There is increasing evidence that NF-kappaB is important in the pathobiology of disease states such as SIRS, MODS and ARDS; therefore, therapeutic interventions aimed at limiting NF-kappaB activation and down-regulating production of inflammatory mediators could prove to be beneficial in decreasing host-derived tissue injury and organ dysfunction. Specific interventions that hold promise for suppressing NF-kappaB activation include the use of antioxidants, inhibition of NIK and the IKK signalsome, treatment with proteasome inhibitors, induction of endotoxin tolerance and, possibly the use of corticosteroids in selected patients.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>9876974</pmid><doi>10.1007/s001340050735</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0342-4642 |
ispartof | Intensive care medicine, 1998-11, Vol.24 (11), p.1131-1138 |
issn | 0342-4642 1432-1238 |
language | eng |
recordid | cdi_proquest_miscellaneous_69115815 |
source | MEDLINE; SpringerLink Journals |
subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Anti-Inflammatory Agents - therapeutic use Antioxidants - therapeutic use Biological and medical sciences Cell Adhesion Molecules - immunology Cytokines - immunology Emergency and intensive care: infection, septic shock Glycoproteins - therapeutic use Humans I-kappa B Kinase Intensive care medicine Interleukins - immunology Medical sciences NF-kappa B - antagonists & inhibitors NF-kappa B - immunology Protein-Serine-Threonine Kinases - antagonists & inhibitors Steroids Systemic Inflammatory Response Syndrome - complications Systemic Inflammatory Response Syndrome - drug therapy Systemic Inflammatory Response Syndrome - immunology |
title | Nuclear factor κ B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T15%3A08%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nuclear%20factor%20%CE%BA%20B:%20a%20pivotal%20role%20in%20the%20systemic%20inflammatory%20response%20syndrome%20and%20new%20target%20for%20therapy&rft.jtitle=Intensive%20care%20medicine&rft.au=CHRISTMAN,%20J.%20W&rft.date=1998-11-01&rft.volume=24&rft.issue=11&rft.spage=1131&rft.epage=1138&rft.pages=1131-1138&rft.issn=0342-4642&rft.eissn=1432-1238&rft.coden=ICMED9&rft_id=info:doi/10.1007/s001340050735&rft_dat=%3Cproquest_pubme%3E69115815%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69115815&rft_id=info:pmid/9876974&rfr_iscdi=true |